Fatty food cravings Similarly, desire for fatty and greasy foods decreased by 14.5 points versus placebo, with the most significant changes appearing around weeks 12-16
Conclusions/interpretation Tirzepatide improves therapeutic target attainment compared with semaglutide in type 2 diabetes
Across these measures, tirzepatide was associated with greater weight loss, higher rates of clinically meaningful weight reduction, and greater improvement in body mass index, systolic and diastolic blood pressure, and haemoglobin A1c
Conflict of interest statement Within the last 36 months, FK has served on scientific advisory panels and/or been part of speaker's bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi and Zealand Pharma
Consult your medical provider before starting any weight loss medication